<DOC>
	<DOCNO>NCT00969826</DOCNO>
	<brief_summary>This study four arm , parallel study . Ten administer single subcutaneous administration 30 , 100 300 μg/kg GCPGC placebo group ( active : placebo=8:2 ) . Eight administer single subcutaneous administration 100 μg/kg Neulasta ( active comparator ) .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor</brief_title>
	<detailed_description>Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 3 week study drug administration . Subjects suitable study admit Clinical Trials Center , Seoul National University Hospital day dose , overnight-fasted 10 p.m. Day -1 . Subjects dose study drug via subcutaneous around 9 a.m. Day 1 . Subjects perform scheduled procedure include clinical laboratory test , electrocardiogram pharmacokinetic pharmacodynamic sampling . Subjects discharge Day 8 , visit Clinical Trials Center Day 9 , Day 11 Day 14 . Study participation terminate post-study visit ( Day 20 - 22 ) .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age : Between 20 40 year age , inclusive ( Age base date give inform consent ) Weight : Between 60 75 kg , within ±20 % ideal body weight Normal clinical laboratory finding , especially ANC value 2000 7500 , inclusive Subject reliable willing make available study period , willing follow study protocol , give write informed consent voluntarily History hypersensitive reaction medication ( aspirin , antibiotic ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease History evidence drug abuse Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use OTC medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) Participation clinical trial drug within 60 day prior participation study Donation whole blood within 60 day unit blood within 30 day prior start study Judged inappropriate study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>GCPGC</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>